PulseSight Therapeutics is a clinical-stage biotech company developing disruptive, non-viral gene therapies dedicated to ophthalmology, with a current focus on age-related macular degeneration (AMD) including late-stage dry AMD/Geographic atrophy (GA) and wet AMD.
Latest news
April 23, 2026
Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
January 26, 2026
PulseSight completes Phase 1 dosing of gene therapy candidate PST-611 in dry AMD and geographic atrophy
January 22, 2026
PulseSight Completes Enrollment in Gene Therapy Trial